Clinical Trials Update: Jan. 22, 2007
Breast Cancer Pancreatic Cancer Hypertension (High Blood Pressure)
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This study will evaluate if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first line chemotherapy in people with breast cancer. Volunteers 18 or older with histologic or cytologic confirmed diagnosis of invasive adenocarcinoma originating in the breast, and who have at least one measurable lesion may be included.
The research sites are in France, Italy, Britain, and the United States.
The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as first line chemotherapy in people with metastatic pancreatic cancer. Candidates 18 or older who have a histologic or cytologic diagnosis of pancreatic adenocarcinoma (locally advanced disease that is not surgically resectable, or distant metastatic disease) may qualify. Participants must have measurable disease as per RECIST guidelines, and must not have received prior chemotherapy, immunotherapy or chemoradiotherapy for advanced pancreatic cancer.
The research sites are located across the United States.
Hypertension (High Blood Pressure)
This study will evaluate two approved medications in investigational dosage combinations to treat high blood pressure. Volunteers at least 18 who have known or suspected high blood pressure may be eligible. Study participants may receive medication, study-related physical exams, and laboratory tests at no cost, and compensation for time and travel.
The research site is in Longwood, Fla.
Copyright 2007 Thomson CenterWatch. All rights reserved.